Levent KEBAPCILAR, Süleyman Hilmi İPEKÇİ, Cem Onur KIRAÇ

Diabetic Ketoacidosis Occurring in Patient on Newly Started Insulin Glargine U300

ISSN: 2564-7784
Yayın Aralığı: 6
Başlangıç: 1990
Yayıncı: Pera Yayıncılık

Insulin glargine U300 is a 3-fold, concentrated, long-acting insulin analog providing a more stable effect compared with insulinglargine U100. However, stable plasma insulin concentration is reached on day 4 of the treatment. Patients with type 1 and type 2diabetes mellitus with decreased insulin reserve are at an increased risk of diabetic ketoacidosis when there is insufficient exoge-nous plasma insulin concentration. Herein, we present a case of diabetic ketoacidosis occurring in a patient with insulin glargineU300 and emphasize the pharmacokinetic properties of insulin glargine U300.

PDF

___

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32: 1335-43. [CrossRef]
Kitabchi AE, Nyenwe EA. Hyperglycemic crises in diabetes mellitus: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am 2006; 35: 725-51. [CrossRef]
Wang F, Zassman S, Goldberg PA. rDNA insulin glargine U300 - a critical appraisal. Diabetes Metab Syndr Obes 2016; 9: 425-41. [CrossRef]
Wallace JP, Wallace JL, McFarland MS. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? Ann Pharmacother 2014; 48: 361-8. [CrossRef]
Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RH. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014; 16: 873-6. [CrossRef]